<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970398</url>
  </required_header>
  <id_info>
    <org_study_id>200816609</org_study_id>
    <nct_id>NCT00970398</nct_id>
  </id_info>
  <brief_title>Effect of an Infant Formula on Infant Growth, Health and Immune Functions</brief_title>
  <official_title>Effect of Infant Formula With Bovine Milk Osteopontin on Infant Growth, Health and Immune functions-a Double-blind Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biostime, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Urbana-Champaign</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biostime, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific objectives of this study are to evaluate the effects of bovine milk osteopontin
      added to infant formula on infant growth, health and immune functions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast-fed infants will be used as a reference group and formula-fed infants will be fed
      control formula or the same formula supplemented with Osteopontin at a concentration 50% or
      100% of that of breast milk. The hypothesis is that supplementation of bovine milk
      Osteopontin in infant formula will have positive effects on infant growth, health and immune
      functions.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of immune cells and cytokines of IL-6, IL-10, and IL-12 in infant's blood samples will be measured to evaluate immune functions.</measure>
    <time_frame>1, 4, and 6 postnatal months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anthropometric parameters: body length, body weight, and head circumferences at each visit.</measure>
    <time_frame>1, 2, 3, 4, 5, and 6 postnatal months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary, stool consistency and well being recorded by 3 day questionnaires</measure>
    <time_frame>1, 2, 3, 4, 5, and 6 postnatal months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and concomitant medications recorded by heath forms as a measure of safety and tolerability.</measure>
    <time_frame>1, 2, 3, 4, 5, and 6 postnatal months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Health</condition>
  <condition>Growth</condition>
  <condition>Immune Functions</condition>
  <arm_group>
    <arm_group_label>Reference group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Human milk breastfeeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard infant formula, with no Osteopontin supplemented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formula with 50% Osteopontin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infant formula supplemented with bovine milk Osteopontin at 50% level of that of breast milk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formula with 100% Osteopontin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infant formula supplemented with bovine milk Osteopontin at 100% level of that of breast milk.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infant formula supplemented with bovine milk Osteopontin</intervention_name>
    <description>Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.</description>
    <arm_group_label>Formula with 50% Osteopontin</arm_group_label>
    <arm_group_label>Formula with 100% Osteopontin</arm_group_label>
    <other_name>Lactopontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard infant formula</intervention_name>
    <description>Infant formula without supplementation of bovine milk Osteopontin</description>
    <arm_group_label>Control formula</arm_group_label>
    <other_name>Lactopontin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Mothers Inclusion Criteria:

          -  Healthy, 19-40 years of age

          -  Plan to exclusively breast-fed or formula-fed

        Infants Exclusion Criteria:

          -  Gestational age &lt; 37 or &gt; 42 weeks

          -  Birth weight &lt; 2.5kg or &gt; 4 kg

          -  Having congenital diseases

          -  Having birth Asphyxia

          -  Having birth infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongmei Peng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Lonnerdal, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000 Feb 4;287(5454):860-4.</citation>
    <PMID>10657301</PMID>
  </reference>
  <reference>
    <citation>Nagatomo T, Ohga S, Takada H, Nomura A, Hikino S, Imura M, Ohshima K, Hara T. Microarray analysis of human milk cells: persistent high expression of osteopontin during the lactation period. Clin Exp Immunol. 2004 Oct;138(1):47-53.</citation>
    <PMID>15373904</PMID>
  </reference>
  <reference>
    <citation>Rollo EE, Hempson SJ, Bansal A, Tsao E, Habib I, Rittling SR, Denhardt DT, Mackow ER, Shaw RD. The cytokine osteopontin modulates the severity of rotavirus diarrhea. J Virol. 2005 Mar;79(6):3509-16.</citation>
    <PMID>15731245</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <last_update_submitted>April 18, 2013</last_update_submitted>
  <last_update_submitted_qc>April 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infant formula</keyword>
  <keyword>Bovine milk Osteopontin</keyword>
  <keyword>growth</keyword>
  <keyword>health</keyword>
  <keyword>immune functions</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

